bluuebunny/crossref_metadata_2025_split huggingface dataset:
1099-P: Sliding Scale Insulin Use in Noncritical Care Settings: Who Can Slide?
Authors: MIGDAL ALEXANDRA , PASQUEL FRANCISCO J. , GALINDO RODOLFO J. , FAYFMAN MAYA , CARDONA SAUMETH , DAVIS GEORGIA , WANG HEQIONG , UMPIERREZ GUILLERMO E. 
Published: June 2019

Despite recommendations of clinical guidelines, sliding scale insulin (SSI) is widely used for the inpatient management of patients with T2D. To understand if there is a population of patients for whom SSI may be an appropriate form of management, we utilized a large database from a single academic institution to define the frequency of SSI usage and determine factors that predict adequate glycemic control with SSI alone in the non-critical care setting. Among 15,348 patients with T2D (28% surgery, 72% medicine), 7,052 (45%) were managed with SSI and 8,296 (55%) with basal insulin. Average admission blood glucose (BG) and HbA1c were lower in patients treated with SSI (154.6±60.3 vs. 191.7±80.8 mg/dl, p&lt;0.001; 7.0±1.5 vs. 8.5±2.1%, p&lt;0.001). Charlson comorbidity score was higher in those treated with basal compared to SSI. Surgical patients were more likely to be treated with SSI than those on medicine services (53% vs. 43%, p&lt;0.001). Hypoglycemia rates were lower with SSI vs. basal insulin (6.9% vs. 14%, p&lt;0.001). Seventy-two percent of patients treated with SSI had an admission BG &lt;180 mg/dl; of them, 93% maintained good glycemic control (mean hospital BG &lt;180 mg/dl). After adjusting for age, gender, BMI, race, Charlson score, and setting (med vs. surg), patients treated with SSI admitted with BG &lt;180 mg/dl had much higher odds of achieving good glycemic control compared to those admitted with BG 180-280 [OR 6.4 (95% CI 5.6, 7.3)] or &gt;280 mg/dl [OR 42.2 (29.5, 60.5)]. Similar results were seen when comparing patients with admission A1c &lt;7% to A1c 7-9% [OR 2.4 (1.9, 2.9)] or A1c &gt;9% [OR 13.3 (8.8, 19.9)].
Conclusion: SSI is used in ~40% of non-critically ill patients, especially among those with mild/moderate hyperglycemia. Most patients with BG &lt;180 mg/dl and A1c &lt;7% treated with SSI maintain good glycemic control (mean hospital BG &lt;180 mg/dl) while hospitalized, suggesting that basal insulin may not be necessary. Further RCT are needed to identify a subpopulation for whom SSI may be appropriate in the hospital.

Disclosure
A. Migdal: None. F.J. Pasquel: Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc. R.J. Galindo: Advisory Panel; Self; Abbott, Novo Nordisk Inc., Sanofi US. Research Support; Self; Novo Nordisk Inc. M. Fayfman: None. S. Cardona: None. G. Davis: None. H. Wang: None. G.E. Umpierrez: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc. Research Support; Self; AstraZeneca, Merck & Co., Inc., Novo Nordisk Inc., Sanofi US.
1104-P: Management of Corticosteroid-Related Hospital Hyperglycemia in the “Real-World”
Authors: PATHAM BHARGAVI , VADHARIYA AISHA , JOHNSON MICHAEL L. , YANDE SOHAM D. , SADHU ARCHANA R. 
Published: June 2019

Guidelines recommend basal bolus insulin for inpatient hyperglycemia management based on studies performed in patients with type 2 diabetes without any corticosteroid therapy. However, in the “real-world,” corticosteroid use is common and complicates management. To better understand insulin use in corticosteroid related hyperglycemia, we conducted a large, retrospective study of patients who were: age &gt;18 years, admission &gt;48 hours, administered insulin &gt;75% of admission, AND administered corticosteroids within the first 2 days of admission. Patients receiving IV insulin or no insulin within two days were excluded. Insulin therapy was categorized into 3 groups based on observed prescribing practices: (a) sliding scale (SS, n=481) (b) basal bolus (BB, n=356), (c) Basal plus (B+, n=386). Each group was analyzed for glucose control: days with hypoglycemia (any &lt;70mg/dl), hyperglycemia (mean &gt;180 mg/dl) or euglycemia (no hypo- or hyperglycemia) and clinical outcomes of length of stay (LOS), 30/60-day readmission, and hospital mortality. Patient and provider factors that influence choice of therapy were controlled using propensity score adjusted models.
BB had fewer hyperglycemic days and lower LOS, albeit more hypoglycemia than SS. B+ had higher hyperglycemic and hypoglycemic days than SS. For corticosteroid related hyperglycemia, BB was a superior insulin regimen in reducing hyperglycemia and LOS.

Disclosure
B. Patham: None. A. Vadhariya: None. M.L. Johnson: None. S.D. Yande: None. A.R. Sadhu: None.
1108-P: The Total Basal Dose (TBD) Is about 35% of Total Daily Dose (TDD) and TBD/Weight Is about 0.23U/kg: 144 Subjects Titrated by Continuous Glucose Monitoring (CGM) while under Dietary Control
Authors: KING ALLEN B. 
Published: June 2019

The current dosing guidelines suggesting TBD is ~ 50% of TDD and TBD = 0.5 U/kg (in T2DM) were based on uncontrolled studies. We have previously published separate controlled studies in pump-treated type 1 (n=39) and type 2 (n=30), multiple daily dosed-treated type 1 (n=49) and basal insulin only-treated type 2 diabetes (n=29). Herein we report the pooled results from these studies. In all studies the dose was titrated by CGM, the diet was the same (50% carbohydrate:30% fat:20%protein) and one meal/d was omitted to establish basal glucose control (except basal insulin-treated T2DM study in which the evening meal was limited to &lt; 18:00h). Carbohydrate-to-insulin (CIR) was established by adjusting the pre-meal bolus so that the 2-4th h post-meal glucose was within 20% of the pre-meal. The resulting mean 24 h basal glucose of each study varied between 100 to 130 mg/dl. There was no significant difference (p &gt; 0.10) in the mean TBD/TDD% and the mean U/kg between groups. When all subjects were then pooled, the mean TBD/kg was 0.232 U/kg (r = 0.601, n= 144) and the TBD/TDD%, 34.5% (r = 0.894, n=115). The mean CIR, g/U = 314/TDD (r = 0.829, n = 115) and 106/TBD (r = 0.747, n = 115). Basal estimation formulas are the same for T1 and T2DM. Current dosing estimation formulas recommend excessive basal and insufficient bolus insulin.

Disclosure
A.B. King: None.
1116-P: Glycemic Outcomes and Persistence with Basal Insulin and Glucagon-Like Peptide-1 Receptor Agonists among Patients with T2D: Simultaneous vs. Sequential Initiation
Authors: PENG XUEJUN V. , AYYAGARI RAJEEV , LUBWAMA ROBERT , VAN VLEET MELVIN J. , SHI LIZHENG , PRICE-HAYWOOD EBONI G. , HOLLANDER PRISCILLA , FONSECA VIVIAN 
Published: June 2019

This real-world retrospective observational analysis was conducted using data from REACHnet, a U.S. regional electronic medical records (EMR) database. Glycemic outcomes after simultaneous or sequential initiation of basal insulin (BI) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA) were evaluated in patients with T2D uncontrolled (A1C ≥7.0%) on oral antidiabetes drugs (OADs). Three patient cohorts were defined: simultaneous BI and GLP-1 RA initiation (Cohort 1; n=109); initiation of BI followed by a GLP-1 RA with a gap of ≤90 days (Cohort 2; n=301); and initiation of BI followed by a GLP-1 RA with a gap of &gt;90 days (Cohort 3; n=459). Baseline mean A1C was very similar across the cohorts (10.3%, 10.3%, and 10.2% in Cohorts 1, 2, and 3, respectively), as were comorbidities including dyslipidemia, hypertension, and obesity. Mean A1C decreased in all 3 cohorts in the 12 months from the date of first BI injection. The greatest mean A1C reductions occurred within 6 months of simultaneous administration (Cohort 1: -2.18%), followed by addition of a GLP-1 RA within 90 days (Cohort 2: -1.77%) and after 90 days (Cohort 3: -1.24%).
Results at 12 months were Cohort 1: -1.66%; Cohort 2: -1.46%; and Cohort 3: -1.32%. Persistence (i.e., non-discontinuation of index treatments) at 12 months was 74.3%, 73.8%, and 80.0% in Cohorts 1, 2, and 3, respectively. Simultaneous initiation resulted in more patients achieving A1C &lt;7.0% at 12 months (33.4%, 24.5%, and 20.9% in Cohorts 1, 2, and 3, respectively); data were statistically significant different between Cohorts 1 and 3 (p=0.0186), but not between Cohorts 1 and 2 or Cohorts 2 and 3.
In conclusion, this retrospective analysis of real-world EMR data in patients with T2D uncontrolled on OADs suggests that simultaneous initiation of BI and a GLP-1 RA resulted in significantly better glycemic control than sequential initiation with a gap of &gt;90 days.

Disclosure
X.V. Peng: Employee; Self; Sanofi. Stock/Shareholder; Spouse/Partner; AbbVie Inc. Stock/Shareholder; Self; AbbVie Inc., Sanofi. R. Ayyagari: Consultant; Self; Sanofi US. Other Relationship; Self; Various pharmaceutical companies. R. Lubwama: Employee; Self; Merck & Co., Inc., Sanofi. M.J. Van Vleet: Employee; Self; Sanofi US. L. Shi: None. E.G. Price-Haywood: None. P. Hollander: Advisory Panel; Self; Novo Nordisk Inc. V. Fonseca: Board Member; Self; American Association of Clinical Endocrinologists. Consultant; Self; Abbott, Asahi Kasei Corporation, Novo Nordisk Inc., Sanofi US, Takeda Pharmaceutical Company Limited. Research Support; Self; Bayer US. Stock/Shareholder; Self; Amgen Inc., BRAVO4HEALTH, Mellitus Health.

Funding
Sanofi U.S.
1120-P: Emotion-Focused CBT Reduces HbA1c Levels in Patients with T2D
Authors: COCCARO EMIL F. , BUSBY ANDREA K. , POTTS TIFFANY M. , PHILIPSON LOUIS H. , DROSSOS TINA 
Published: June 2019

A relationship between HbA1c levels and emotional regulation in T1/T2 diabetes has been reported. Accordingly, we developed a 10-session Emotion-Focused Cognitive Behavioral Treatment (EF-CBT) program to address this issue. Twenty patients with T2D were equally randomized to EF-CBT and Treatment As Usual (TAU). While both displayed HbA1c reductions mid-trial, the EF-CBT group showed a larger reduction [-1.23 ± 1.11 (d = 1.11)] compared with TAU [-0.67 ± 1.11 (d = 0.61)]. The difference at end- (d = 0.49), but not mid- (d = 0.03) trial, is likely because most EF-CBT elements are after mid-trial. Correlations between changes in HbA1c levels and in diabetes distress (r = 0.57)/Emotion Regulation (r = -0.52), both p &lt; 0.02), were also observed at end-trial.

Disclosure
E.F. Coccaro: Consultant; Self; Avanir, Inc. Other Relationship; Self; Azevan, Inc. A.K. Busby: None. T.M. Potts: None. L.H. Philipson: Research Support; Self; Jaeb Center for Health Research, Johnson & Johnson. T. Drossos: None.

Funding
Chicago Center for Diabetes Translation Research (P30DK092949); University of Chicago
1122-P: Physiological Effects of Pioglitazone in Ataxia-Telangiectasia
Authors: MCCREIGHT LAURA J. , MARI ANDREA , PEARSON EWAN 
Published: June 2019

Aims: Ataxia telangiectasia (A-T) is a rare genetic condition associated with diabetes. OGTT data show that nondiabetic adults with A-T are insulin resistant. ATM-ko mice are glucose intolerant, insulin resistant with abnormal fat distribution, which improve with TZD treatment. The RAMP study assessed the effects of pioglitazone in A-T.
Methods: This open label, non-randomised, crossover study compared 8 nondiabetic people with A-T and 15 healthy controls. Dual tracer mixed meal tests, indirect calorimetry, and adipocyte function were used to assess response to treatment.
Results: Groups were matched for age, BMI and HbA1c. Pioglitazone reduced fasting (61 [IQR 26 - 135] to 28.0 [IQR 20.9 - 110.1] pmol/l, p=0.008) and meal (393 [IQR 275 - 2103] to 252 [IQR 195 - 823], p=0.02) insulin in the A-T group, with unchanged fasting but reduced mean glucose (6.3 [IQR 6.1 - 6.7] to 5.9 [IQR 5.7 - 6.2] mmol/l, p=0.02). Pioglitazone did not affect glucose or insulin in controls. Pioglitazone improved insulin sensitivity in the A-T group, with reduced HOMA-IR (2.19 [IQR 0.96 - 4.14] to 0.97 [IQR 0.76 - 3.54], p=0.023) and increased Matsuda index (2.7 [IQR 1.2 - 5.9] to 5.3 [IQR 1.6 - 7.1], p=0.008). Pioglitazone increased adiponectin in both groups (A-T: 2528 [IQR 2008 - 4887] to 12461 [IQR 4451 - 15843] ng/ml, p=0.008; control 6262 [IQR 4051 - 89940] to 15123 [IQR 9594 - 19384] ng/ml, p=0.001). NEFAs were reduced in A-T (0.25 [IQR 0.22 - 0.28] to 0.18 [IQR 0.14 - 0.20] mmol/l, p=0.016). Pioglitazone increased the fasting respiratory quotient (RQ) in A-T (0.9 [IQR 0.8 - 1.0] to 1.1 [IQR 1.0 - 1.2], p=0.04). A mixed effects model of insulin sensitivity identified a significant gene * drug interaction (p=0.001) between A-T and pioglitazone.
Conclusion: Pioglitazone treatment improved insulin sensitivity and adipocyte function in A-T. Pioglitazone reduced NEFAs and increased RQ, indicating a reduction in fatty acid oxidation. These data suggest that pioglitazone may be an appropriate first line treatment for diabetes in A-T.

Disclosure
L.J. McCreight: None. A. Mari: Consultant; Self; Eli Lilly and Company. Research Support; Self; Boehringer Ingelheim International GmbH. E. Pearson: None.

Funding
UK Wellcome Trust (to E.P.)
1126-P: Comparison of Telmisartan vs. Valsartan on Cardiovascular and Renal Biomarkers in 84 Patients with T2DM with Microalbuminuria
Authors: GUPTA VISHAL , TELI VAISHALI 
Published: June 2019

84 T2DM with microalbuminuria (eUACR) &gt;30 aged 18-75 years irrespective of their A1c, on standard glucose, lipid and BP lowering therapy using telmisartan (Tm) or valsartan (Vs) were followed-up for 2 years. 2 groups were identified, Tm group and Vs group. Renal (Cr, eGFR, UACR) and CV (BP, BMI, Lipid profile, hs-CRP) markers were evaluated at 3-6 month intervals for 2 years. NT-ProBNP was measured at the end of 2 years. Patients with history of major surgery, coronary intervention, IHD or hospitalization in last 1 year, eGFR &lt;45, potassium &gt;5.5 were excluded. Data was analyzed using PSPP version 1.0.1 and represented as Mean (SD) and independent sample t-test and paired t-test was used. P value of 0.05 was considered to be significant.
Results: Baseline therapeutic, renal and CV parameters were well matched in both groups. Mean Tm dose was 86.19mg (SD ± 69.63) and Vs 153.33mg (SD ± 83.77). Within Tm group, mean A1c 1.43% (95% CI 0.95-1.92, p-&lt;0.001), SBP 9.19mm (95% CI 2.58-15.80, p-0.008), TC 38.68mg% (95% CI 26.73-50.63, p-&lt;0.001), LDL 28.35 (95% CI 17.14-39.56, p-&lt;0.001), TG 39.15 (95% CI 20.82-57.47, p-&lt;0.001), Cr 10.66 (95% CI 5.62-15.71, p&lt;0.001), non-HDL 49.42 (95% CI 33.79-65.05, p-&lt;0.001), UACR 87.62 (95% CI 17.03-158.21, p-0.016) reduced significantly. Within Vs group, mean A1c 1.09% (95% CI 0.81-1.38, p-&lt;0.001), TC 24.63mg% (95% CI 15.81-33.46, p-&lt;0.001), LDL 16.67 (95% CI 7.07-26.28, p-0.001), TG 59.26 (95% CI 25.10-53.42, p-&lt;0.001), Cr 15.15 (95% CI 9.28-21.02, p-&lt;0.001), non-HDL 42.57 (95% CI 29.77-55.37, p-&lt;0.001) reduced and HDL 5.98 (95% CI 2.81-9.14, p-0.001) increased significantly. At the end of 2 years there was no difference see in any CV or renal parameter between both groups. NT-ProBNP (Tm 149.16 (±153.36) vs. Vs 203.47 (±335.40), p 0.343) remained high in both groups.
Conclusion: Tm is as effective as Vs with respect to control of CV and renal parameters in T2DM patients with microalbuminuria however NT-ProBNP remained elevated in both groups.

Disclosure
V. Gupta: None. V. Teli: None.
1127-P: SGLT2 Inhibition (SGLT2i) Mediated Urinary Glucose Excretion (UGE) Associations with Metabolic and Renal Hemodynamic Parameters
Authors: LYTVYN YULIYA , LYTVYN ANDRIY , MUSCELLI ELZA O. , PERKINS BRUCE A. , CHERNEY DAVID , FERRANNINI ELE 
Published: June 2019

The metabolic and hemodynamic correlates of SGLT2i-mediated UGE in patients with diabetes are not well understood. Accordingly, in this post hoc analysis, we measured UGE in 66 T2D, 37 T1D, and 25 nondiabetic (ND) participants under baseline conditions and following treatment with an SGLT2i (empagliflozin, 25 mg/d, EMPA). Measurements were taken during 3 h of fasting and 5 h of a mixed meal absorption (T2D and ND) or under usual clinical conditions in patients with T1D. Fractional glucose excretion (FEGlu) was obtained as the ratio of UGE to the filtered glucose load (=GFR x plasma glucose concentration [G]). In T1D participants only, ERPFPAH and GFRINULIN were measured and intraglomerular pressure (PGLO) estimated.
With EMPA, FEGlu was 38±12% and 46±11% in T2D (fasting and post meal, respectively), 26±11% and 36±8% in ND, and 45±21% in T1D. In the pooled T1D, T2D and ND cohort, overall effect of EMPA on FEGlu was 39±11%; in this model, [G] was a positive determinant (FEGlu=34% at a [G] of 100 mg/dL and 44% at a [G] of 200 mg/dL, r=0.38, p&lt;0.0001), whereas presence of T1D, T2D or ND was not. After adjusting for [G], plasma insulin concentration was also a positive determinant of FeGlu (r=0.12, p=0.01), adding 3% to FEGlu at the mean post meal plasma insulin of 50 µU/mL in T2D and ND; likewise, in T1D, FEGlu was related to the mean daily insulin dose (r=0.41, p&lt;0.01). As described in previous work, in T1D, EMPA decreased ERPF and increased renal vascular resistance (p&lt;0.01). Estimated PGLO was reduced (59.0±6.7 to 56.5±4.6 mmHg, p=0.038), and its change from baseline was associated with a larger increment in FEGlu (r=0.48, p=0.003.
In conclusion, SGLT2i effects on renal glucose reabsorption are consistent across the spectrum of glucose tolerance. Moreover, FEGlu is a function of ambient hyperglycemia and, to a lesser extent, insulinemia. Finally, in T1D, decrements in renal hyperfiltration are related to greater glycosuria, possibly as a function of natriuresis.

Disclosure
Y. Lytvyn: None. A. Lytvyn: None. E.O. Muscelli: None. B.A. Perkins: Advisory Panel; Self; Abbott, Boehringer Ingelheim International GmbH, Boehringer Ingelheim International GmbH, Insulet Corporation. Research Support; Self; Boehringer Ingelheim International GmbH. Other Relationship; Self; Abbott, Boehringer Ingelheim International GmbH, Lilly Diabetes, Medtronic, Novo Nordisk Inc., Sanofi. D. Cherney: Other Relationship; Self; AbbVie Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Prometic Life Sciences Inc., Sanofi. E. Ferrannini: None.
1131-P: Endoscopic Duodenal Submucosal Laser Ablation for the Treatment of Type 2 Diabetes Mellitus: Results of First-in-Human Pilot Study
Authors: MRAZ MILOS , MARCOVITCH IDAN , LANKOVA IVANA , KRATOCHVILOVA HELENA , CINKAJZLOVA ANNA , BENES MAREK , KORNER JUDITH , VLASAKOVA ZUZANA , SPICAK JULIUS , PELIKANOVA TEREZIE , HALUZIK MARTIN 
Published: June 2019

The duodenum has recently emerged as a key regulator in glucose metabolism via modulation of a complex network of neural and hormonal signals in response to ingested food. DiaGone™ is an endoscopic device which utilizes precisely controlled laser technology to target the duodenal submucosal neural plexi with the aim of improving glucose control by modulating the gastrointestinal neurohumoral axis. Nine subjects (5 males) with obesity (BMI 34.0 ± 4.6 kg/m2) and type 2 diabetes mellitus (T2DM) insufficiently controlled on metformin were included in this first-in-human trial in order to assess the efficacy and safety of DiaGone™. Subjects were instructed to continue with regular diet 24h after the procedure and metformin dose was not changed during the study period. Biochemical and anthropometric parameters were assessed at baseline and 3 and 6 months after the procedure and continuous glucose monitoring (CGM) and a standard liquid meal test were performed at baseline and 3 months after the procedure. DiaGone™ significantly decreased HbA1C from 78.3 ± 13.3 mmol/mol at baseline to 64.9 ± 6.4 mmol/mol and 64.8 ± 7.1 mmol/mol at 3 and 6 months, respectively (p&lt;0.01). Similarly, a decrease in fasting glucose levels was noted (12.4 ± 3.5 vs. 9.5 ± 2.0 vs. 9.7 ± 2.7 mmol/l, p&lt;0.01) with no significant changes in fasting insulin levels. Glucose AUC during the 150 min meal test 3 months after the procedure showed a reduction of 20% from baseline (43,435 vs. 34,096, p&lt;0.01). No significant changes were observed in AUC for insulin. No adverse events related to the procedure or significant changes in weight were reported throughout the 6-month period.
In conclusion, these pilot results suggest that endoscopic duodenal submucosal laser ablation using the DiaGone™ device is associated with improvements in both baseline and postprandial glycemia as well as HbA1C with no significant changes in insulin levels or body weight while having a favorable safety and tolerability profile.

Disclosure
M. Mraz: None. I. Marcovitch: Employee; Self; Digma Medical. I. Lankova: None. H. Kratochvilova: None. A. Cinkajzlova: None. M. Benes: None. J. Korner: Board Member; Self; Digma Medical. Stock/Shareholder; Self; Digma Medical. Z. Vlasakova: None. J. Spicak: None. T. Pelikanova: None. M. Haluzik: None.

Funding
MH CZ - DRO; Institute for Clinical and Experimental Medicine (IN00023001); RVO (VFN64165)
1137-P: Remission of Type 2 Diabetes (T2DM) in 33.6% (51 of 152) Hypogonadal Men Receiving Long-Term Testosterone Therapy for Up to 12 Years in a Real-Life Registry Study
Authors: HAIDER KARIM S. , HAIDER AHMAD , SAAD FARID 
Published: June 2019

Background: In the 2018 ADA Standards of Medical Care in Diabetes checking testosterone in men with diabetes was added as new recommendation.
Methods: A registry of hypogonadal men (testosterone ≤12.1 nmol/L) was initiated in 2004 in a urological setting. By 2018, 324 of 823 patients (39%) had T2DM diagnosed and treated in a diabetes center. 152 of these men received testosterone undecanoate (TU) injections 1000 mg/12 weeks (T-group) following an initial 6-week interval. Anthropometric and metabolic parameters were measured at least twice a year and fasting insulin obtained from the diabetes center to calculate HOMA-IR.
Results: Mean follow-up was 7.9, maximum 12 years. 51 patients (33.6%) were in remission at the last measurement. Their average baseline age was 61±4.11 years. HbA1c dropped from 8.6±1.01% at baseline to 5.45±0.18%, fasting glucose from 7.8±1.2 mmol/L to 5.4±0.09 mmol/L. HOMA-IR dropped from 9.76±2.74 to 1.98±0.54. Triglycerides decreased from 3.41±0.57 to 2.18±0.11 mmol/L. Anthropometric parameters: Body weight declined progressively from 112.9±13.2 to 90.2±7.4 kg, waist circumference from 110.7±7.6 to 97.8±4.6 cm. All patients had been on oral antidiabetic medication (metformin) at baseline. 17 patients were on insulin at an average dose of 25.3±5.9 units per day. The average observation time was 124.1±22.7 months (10.3±1.9 years). The average time to discontinuation of diabetes medication was 107.2 months (8.9 years). Medication adherence to TU was 100% as all injections were administered in the urology office and documented.
Discussion: The registry was not designed to study the effects of testosterone on T2DM. Remission of T2DM has not been described in the literature and was unexpected.
Conclusions: Long-term testosterone treatment in hypogonadal men may result in remission of T2DM.

Disclosure
K.S. Haider: Speaker's Bureau; Self; Bayer AG. A. Haider: Research Support; Self; Bayer AG. Speaker's Bureau; Self; Bayer AG. F. Saad: Employee; Self; Bayer AG. Stock/Shareholder; Self; AbbVie Inc., Amgen Inc., Bayer AG.

Funding
Bayer AG